MX2021003606A - Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. - Google Patents

Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.

Info

Publication number
MX2021003606A
MX2021003606A MX2021003606A MX2021003606A MX2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A MX 2021003606 A MX2021003606 A MX 2021003606A
Authority
MX
Mexico
Prior art keywords
type
treatment
sulfonamide compounds
collagen diseases
biphenyl sulfonamide
Prior art date
Application number
MX2021003606A
Other languages
English (en)
Inventor
Radko Komers
Celia Jenkinson
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of MX2021003606A publication Critical patent/MX2021003606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar el síndrome de Alport y otras enfermedades asociadas con la deficiencia de colágeno tipo IV, y para prevenir la sordera asociada con los mismos, que comprenden administrar un compuesto que tiene la estructura (I), o una sal farmacéuticamente aceptable del mismo, o administrar una composición farmacéutica que comprende el compuesto de la estructura (I) o una sal farmacéuticamente aceptable del mismo.
MX2021003606A 2018-10-04 2019-10-03 Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. MX2021003606A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US201962894559P 2019-08-30 2019-08-30
PCT/US2019/054559 WO2020072814A1 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Publications (1)

Publication Number Publication Date
MX2021003606A true MX2021003606A (es) 2021-08-16

Family

ID=68318947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003606A MX2021003606A (es) 2018-10-04 2019-10-03 Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.

Country Status (12)

Country Link
US (1) US11207299B2 (es)
EP (1) EP3860594A1 (es)
JP (1) JP2022514152A (es)
KR (1) KR20210081338A (es)
CN (1) CN113286587A (es)
AU (1) AU2019354784A1 (es)
BR (1) BR112021006132A2 (es)
CA (1) CA3114434A1 (es)
IL (1) IL281965A (es)
MA (1) MA53817A (es)
MX (1) MX2021003606A (es)
WO (1) WO2020072814A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017985A (zh) 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
WO2022246200A1 (en) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
WO2024101440A1 (ja) * 2022-11-11 2024-05-16 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CZ200172A3 (cs) 1998-07-06 2001-08-15 Bristol-Myers Squibb Company Bifenylsulfonamidy jako duální antagonisty receptoru angiotensinového a endothelinového receptoru
ATE339417T1 (de) 1999-12-15 2006-10-15 Bristol Myers Squibb Co Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
CN117017985A (zh) 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN114126712A (zh) 2018-12-21 2022-03-01 特拉维尔治疗公司 无定形司巴森坦（sparsentan）组合物

Also Published As

Publication number Publication date
KR20210081338A (ko) 2021-07-01
EP3860594A1 (en) 2021-08-11
IL281965A (en) 2021-05-31
US11207299B2 (en) 2021-12-28
AU2019354784A1 (en) 2021-04-15
JP2022514152A (ja) 2022-02-10
MA53817A (fr) 2021-08-11
CA3114434A1 (en) 2020-04-09
WO2020072814A1 (en) 2020-04-09
US20200147050A1 (en) 2020-05-14
BR112021006132A2 (pt) 2021-07-20
CN113286587A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
AU2018271990A1 (en) Covalent inhibitors of KRAS
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2020008359A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.
MX2021002321A (es) Nuevos metodos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
MX2019009235A (es) Compuestos antifibroticos.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2021009717A (es) Sulfonamidas biciclicas.
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof